Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve Pubget Overpricing |
lüll New therapeutic agents for diabetes mellitus: implications for anesthetic management Chen D; Lee SL; Peterfreund RAAnesth Analg 2009[Jun]; 108 (6): 1803-10Multiple hormones and transmitter systems contribute to glucose homeostasis and the control of metabolism. Recently, the gastrointestinal peptide hormones glucagon-like peptide 1 and amylin have been shown to significantly contribute to this complex physiology. These advances provide the foundation for new treatments for diabetes mellitus. Therapies based on glucagon-like peptide 1 and amylin have now been introduced into clinical practice. Rimonabant, the selective endocannabinoid receptor antagonist, had been used in European countries for the treatment of obesity; it has recently been withdrawn for this indication. This drug exhibited therapeutic benefits for metabolic variables and for type 2 diabetes mellitus. Anesthesia providers caring for patients with diabetes mellitus will need to understand the implications of these new therapies in perioperative settings, particularly with respect to side effects and interactions.|*Anesthesia[MESH]|Amyloid/therapeutic use[MESH]|Animals[MESH]|Cannabinoid Receptor Modulators/physiology[MESH]|Diabetes Mellitus/*drug therapy[MESH]|Glucagon-Like Peptide 1/therapeutic use[MESH]|Humans[MESH]|Hypoglycemic Agents/*adverse effects/*therapeutic use[MESH]|Incretins/physiology[MESH]|Islet Amyloid Polypeptide[MESH] |